Holly Buckley

So I don't know if it's going to be floodgates, but I think we will see growth in healthcare private equity deals through the end of the year, but not a massive amount, but some increase from where we're at right now.

Yeah, I mean, I think behavioral health still. I think one of the really interesting things that was a surprise to me was an interest in Medicaid-heavy businesses, which I thought were going to be somewhat DOA in light of the proposed Medicaid cuts that are going through the federal budget process right now. But there was a fair amount of

Yeah, I mean, I think behavioral health still. I think one of the really interesting things that was a surprise to me was an interest in Medicaid-heavy businesses, which I thought were going to be somewhat DOA in light of the proposed Medicaid cuts that are going through the federal budget process right now. But there was a fair amount of

Yeah, I mean, I think behavioral health still. I think one of the really interesting things that was a surprise to me was an interest in Medicaid-heavy businesses, which I thought were going to be somewhat DOA in light of the proposed Medicaid cuts that are going through the federal budget process right now. But there was a fair amount of

I'd say excitement around the possibilities of investing in Medicaid-focused businesses that were involved in doing those better. And so I think a lot of folks saw opportunity with that. So for example, if the work requirements become a much bigger factor, there's potentially opportunities for funds looking to invest in how to better facilitate the work requirements.

I'd say excitement around the possibilities of investing in Medicaid-focused businesses that were involved in doing those better. And so I think a lot of folks saw opportunity with that. So for example, if the work requirements become a much bigger factor, there's potentially opportunities for funds looking to invest in how to better facilitate the work requirements.

I'd say excitement around the possibilities of investing in Medicaid-focused businesses that were involved in doing those better. And so I think a lot of folks saw opportunity with that. So for example, if the work requirements become a much bigger factor, there's potentially opportunities for funds looking to invest in how to better facilitate the work requirements.

And I think just Medicaid being so big and so important, but with the federal government so focused on it, I think we are going to see a fair amount of focus there. I think the other big provider area that we continue to see really big interest in is infusion. I think with the growing significance of specialty medicine and individualized medicine and

And I think just Medicaid being so big and so important, but with the federal government so focused on it, I think we are going to see a fair amount of focus there. I think the other big provider area that we continue to see really big interest in is infusion. I think with the growing significance of specialty medicine and individualized medicine and

And I think just Medicaid being so big and so important, but with the federal government so focused on it, I think we are going to see a fair amount of focus there. I think the other big provider area that we continue to see really big interest in is infusion. I think with the growing significance of specialty medicine and individualized medicine and

in the push to get healthcare out of more expensive venues and into the home and more affordable outpatient venues, infusion remains really high on the interest list for a lot of firms.

in the push to get healthcare out of more expensive venues and into the home and more affordable outpatient venues, infusion remains really high on the interest list for a lot of firms.

in the push to get healthcare out of more expensive venues and into the home and more affordable outpatient venues, infusion remains really high on the interest list for a lot of firms.

Yeah, I'd say life sciences and pharma services deals are still of really big interest. So clinical trials, contract manufacturing, and things like that. But also looking at automation in the pharma services space and the use of AI in pharma services was something we heard a fair amount of discussion around.

Yeah, I'd say life sciences and pharma services deals are still of really big interest. So clinical trials, contract manufacturing, and things like that. But also looking at automation in the pharma services space and the use of AI in pharma services was something we heard a fair amount of discussion around.

Yeah, I'd say life sciences and pharma services deals are still of really big interest. So clinical trials, contract manufacturing, and things like that. But also looking at automation in the pharma services space and the use of AI in pharma services was something we heard a fair amount of discussion around.

So AI's role in clinical trial design, drug discovery, decentralized trial management, as well as just kind of automation around the entire pharma services spectrum. So around things like the compliance function. So I think we'll continue to see a lot of interest there.

So AI's role in clinical trial design, drug discovery, decentralized trial management, as well as just kind of automation around the entire pharma services spectrum. So around things like the compliance function. So I think we'll continue to see a lot of interest there.

So AI's role in clinical trial design, drug discovery, decentralized trial management, as well as just kind of automation around the entire pharma services spectrum. So around things like the compliance function. So I think we'll continue to see a lot of interest there.

And then a lot on the digital health side, like how can we automate different parts of the healthcare cycle, as well as kind of the integration with payers. So again, just less on the direct provider services, provision of care side, and more on the support services around the delivery of care.